Cara Therapeutics Completes Phase 1b Trial Of I.V. CR845 In Dialysis Patients

(RTTNews) - Cara Therapeutics, Inc. (CARA), a biotechnology company, Wednesday announced the successful completion of a Phase 1b trial of an intravenous formulation of CR845 in dialysis patients.

In the repeat dosing of I.V. CR845 over one week was observed to be safe and was well-tolerated across a five-fold dose range. The trial established a dosing regimen for the ongoing Phase 2 trial in dialysis patients with uremic pruritus.

The company expects to report top-line data from this trial in the first half of 2015.

There are currently no approved therapeutics in the U.S. for uremic pruritus, an intractable type of itch that is resistant to conventional treatments, and diminishes the quality of life for almost half of all kidney dialysis patients.

The Phase 1b trial was a double-blind, randomized, placebo-controlled trial designed to evaluate the safety and pharmacokinetics of I.V. CR845 in 24 hemodialysis patients.